Molecular Partners AG

The company is a clinical-stage biotechnology company focused on designing and developing DARPin therapeutics. These therapeutics are a new class of custom-built protein drug candidates based on natural binding proteins. The company's programs are in various stages of preclinical and clinical development, with a primary focus on oncology. DARPin therapeutics have been clinically validated across several therapeutic areas and developed to the registrational stage. The company utilizes the properties of DARPins, including high affinity and specificity, small size, flexible architecture, and high stability, to design differentiated therapeutics for cancer patients. These include targeted radiopharmaceuticals and next-generation immune cell engagers. DARPin candidates have been tested in preclinical studies and clinical trials, involving over 2,500 patients, and have shown high activity and general tolerability. The company has designed product candidates with multiple mechanisms of action (MoAs), such as blocking growth factors, localizing activity, conditionally activating immune cells (e.g., logic-gated Switch-DARPins), delivering cytotoxic payloads and radionuclides (e.g., Radio-DARPins), neutralizing viruses, adjusting half-life, and initiating cell death. The company applies these features across its portfolio to achieve specific therapeutic responses. Its DARPin platforms, including Radio-DARPins and Switch-DARPins, are designed to yield novel product candidates with broad therapeutic applications.